Icon PLC's stock experienced a significant after-hours plunge of 11.36% following the release of its fourth quarter and full year 2025 financial results, which revealed both an earnings miss and the need to restate previous financial statements.

The company reported adjusted earnings per share of $2.52 for the quarter, falling short of analyst estimates of $3.13 by 19.49%. While quarterly sales of $2.113 billion exceeded expectations, the earnings disappointment was compounded by the disclosure of accounting issues that require financial restatements.

Icon announced that an audit committee investigation uncovered improper adjustments to clinical trial services revenue from the third quarter of 2023 through the fourth quarter of 2024. The company determined that revenue was overstated by 0.8% in 2023 and 1.1% in 2024, and identified material weaknesses in its internal control over financial reporting. Additionally, full-year operating income dropped 57.1% to $442.8 million, further contributing to investor concerns about the company's financial health and reporting practices.